• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抑制性抗体诱导的活性尿激酶的酶原再激活。

Rezymogenation of active urokinase induced by an inhibitory antibody.

机构信息

State Key Laboratory of Structural Chemistry, Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, 155 Yang Qiao West Road, Fuzhou, Fujian, 350002, China.

出版信息

Biochem J. 2013 Jan 1;449(1):161-6. doi: 10.1042/BJ20121132.

DOI:10.1042/BJ20121132
PMID:23016918
Abstract

An important regulatory mechanism of serine proteases is the proteolytic conversion of the inactive pro-enzyme, or zymogen, into the active enzyme. This activation process is generally considered an irreversible process. In the present study, we demonstrate that an active enzyme can be converted back into its zymogen form. We determined the crystal structure of uPA (urokinase-type plasminogen activator) in complex with an inhibitory antibody, revealing that the antibody 'rezymogenizes' already activated uPA. The present study demonstrates a new regulatory mechanism of protease activity, which is also an extreme case of protein allostery. Mechanistically, the antibody binds a single surface-exposed loop, named the autolysis loop, thereby preventing the stabilization of uPA in its active conformation. We argue that this autolysis loop is a key structural element for rezymogenation of other proteases, and will be a new target site for pharmacological intervention with serine protease activity.

摘要

丝氨酸蛋白酶的一个重要调控机制是将无活性的原酶(酶原)切割转化为有活性的酶。这一激活过程通常被认为是一个不可逆的过程。在本研究中,我们证明了一种活性酶可以被重新转化为其酶原形式。我们确定了与抑制性抗体结合的 uPA(尿激酶型纤溶酶原激活物)的晶体结构,揭示了抗体“再酶原化”已经激活的 uPA。本研究证明了蛋白酶活性的一种新调控机制,这也是蛋白质变构作用的一个极端案例。从机制上讲,抗体结合到一个单一的暴露于表面的环,即自溶环,从而阻止 uPA 稳定在其活性构象中。我们认为这个自溶环是其他蛋白酶再酶原化的关键结构元件,也将成为丝氨酸蛋白酶活性的药理学干预的新靶点。

相似文献

1
Rezymogenation of active urokinase induced by an inhibitory antibody.抑制性抗体诱导的活性尿激酶的酶原再激活。
Biochem J. 2013 Jan 1;449(1):161-6. doi: 10.1042/BJ20121132.
2
Targeting the autolysis loop of urokinase-type plasminogen activator with conformation-specific monoclonal antibodies.针对尿激酶型纤溶酶原激活物的自溶环的构象特异性单克隆抗体。
Biochem J. 2011 Aug 15;438(1):39-51. doi: 10.1042/BJ20110129.
3
Activation of the zymogen to urokinase-type plasminogen activator is associated with increased interdomain flexibility.酶原向尿激酶型纤溶酶原激活物的激活与结构域间柔韧性的增加有关。
J Mol Biol. 2011 Aug 12;411(2):417-29. doi: 10.1016/j.jmb.2011.05.026. Epub 2011 Jun 6.
4
A novel mode of intervention with serine protease activity: targeting zymogen activation.一种具有丝氨酸蛋白酶活性的新型干预模式:靶向酶原激活。
J Biol Chem. 2009 Feb 13;284(7):4647-57. doi: 10.1074/jbc.M804922200. Epub 2008 Dec 1.
5
Nonproteolytic induction of catalytic activity into the single-chain form of urokinase-type plasminogen activator by dipeptides.二肽对单链尿激酶型纤溶酶原激活剂催化活性的非蛋白水解诱导作用
Biochemistry. 2009 Oct 13;48(40):9606-17. doi: 10.1021/bi900510f.
6
The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.前列腺癌DU145细胞表面介导了乳腺丝抑蛋白对尿激酶型纤溶酶原激活剂的抑制作用。
Cancer Res. 2000 Sep 1;60(17):4771-8.
7
Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.受体介导的纤溶酶原激活物功能调节:两种直接膜锚定形式的尿激酶对纤溶酶原的激活作用
J Pept Sci. 2000 Sep;6(9):432-9. doi: 10.1002/1099-1387(200009)6:9<432::AID-PSC279>3.0.CO;2-Q.
8
A site-directed mutagenesis of pro-urokinase which substantially reduces its intrinsic activity.一种对尿激酶原进行的定点诱变,可大幅降低其内在活性。
Biochemistry. 1996 Nov 12;35(45):14070-6. doi: 10.1021/bi9605393.
9
Structure of human pro-chymase: a model for the activating transition of granule-associated proteases.人组织蛋白酶原的结构:颗粒相关蛋白酶激活转变的模型。
Biochemistry. 2003 Mar 11;42(9):2616-24. doi: 10.1021/bi020594d.
10
The receptor for urokinase-type plasminogen activator of a human keratinocyte line (HaCaT).一种人角质形成细胞系(HaCaT)的尿激酶型纤溶酶原激活剂受体。
Exp Cell Res. 1994 Oct;214(2):486-98. doi: 10.1006/excr.1994.1286.

引用本文的文献

1
Allosteric inhibition of HTRA1 activity by a conformational lock mechanism to treat age-related macular degeneration.变构抑制 HTRA1 活性的构象锁机制治疗年龄相关性黄斑变性。
Nat Commun. 2022 Sep 5;13(1):5222. doi: 10.1038/s41467-022-32760-9.
2
Halogen bonding for the design of inhibitors by targeting the S1 pocket of serine proteases.通过靶向丝氨酸蛋白酶的S1口袋设计抑制剂的卤键作用。
RSC Adv. 2018 Aug 6;8(49):28189-28197. doi: 10.1039/c8ra03145b. eCollection 2018 Aug 2.
3
Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat.
抑肽酶对TMPRSS2相关丝氨酸蛋白酶共价抑制机制的结构基础
J Virol. 2021 Sep 9;95(19):e0086121. doi: 10.1128/JVI.00861-21. Epub 2021 Jun 23.
4
Structure of an affinity-matured inhibitory recombinant fab against urokinase plasminogen activator reveals basis of potency and specificity.针对尿激酶型纤溶酶原激活物的亲和成熟抑制性重组 Fab 结构揭示了效力和特异性的基础。
Biochim Biophys Acta Proteins Proteom. 2021 Feb;1869(2):140562. doi: 10.1016/j.bbapap.2020.140562. Epub 2020 Nov 19.
5
Crystal structure, epitope, and functional impact of an antibody against a superactive FVIIa provide insights into allosteric mechanism.一种针对超活性FVIIa的抗体的晶体结构、表位及功能影响为变构机制提供了见解。
Res Pract Thromb Haemost. 2019 Jun 20;3(3):412-419. doi: 10.1002/rth2.12211. eCollection 2019 Jul.
6
Solution Structure of SpoIVB Reveals Mechanism of PDZ Domain-Regulated Protease Activity.SpoIVB的溶液结构揭示了PDZ结构域调节蛋白酶活性的机制。
Front Microbiol. 2019 Jun 12;10:1232. doi: 10.3389/fmicb.2019.01232. eCollection 2019.
7
6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.6-取代己二烯基氨甲酰基密胺衍生物作为人尿激酶型纤溶酶原激活物的高效和选择性抑制剂在癌症中的应用。
J Med Chem. 2018 Sep 27;61(18):8299-8320. doi: 10.1021/acs.jmedchem.8b00838. Epub 2018 Sep 7.
8
Ligand binding modulates the structural dynamics and activity of urokinase-type plasminogen activator: A possible mechanism of plasminogen activation.配体结合调节尿激酶型纤溶酶原激活剂的结构动力学和活性:纤溶酶原激活的一种可能机制。
PLoS One. 2018 Feb 8;13(2):e0192661. doi: 10.1371/journal.pone.0192661. eCollection 2018.
9
Non-canonical proteolytic activation of human prothrombin by subtilisin from may shift the procoagulant-anticoagulant equilibrium toward thrombosis.来自[具体来源未提及]的枯草杆菌蛋白酶对人凝血酶原的非经典蛋白水解激活可能会使促凝血-抗凝血平衡向血栓形成方向转变。
J Biol Chem. 2017 Sep 15;292(37):15161-15179. doi: 10.1074/jbc.M117.795245. Epub 2017 Jul 6.
10
Discovery of a novel conformational equilibrium in urokinase-type plasminogen activator.尿激酶型纤溶酶原激活物中新型构象平衡的发现。
Sci Rep. 2017 Jun 13;7(1):3385. doi: 10.1038/s41598-017-03457-7.